Drug Profile
Crotedumab
Alternative Names: REGN-1193Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Developer Regeneron Pharmaceuticals
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (Parenteral)
- 10 May 2016 Regeneron terminates a phase I trial in Type-2 diabetes mellitus in USA (NCT02284425)